Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited announced today that a Notice of Allowance has been received from the European Patent Office (EPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell technology. The patent application entitled “Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines” is owned by the University of Wisconsin– Madison’s Wisconsin Alumni Research Foundation (WARF) and is among the intellectual property licensed exclusively from WARF to Cynata.
The Notice of Allowance is sent to the applicant when the EPO intends to issue a patent. The patent will expand the already strong IP protection of the Cymerus platform and its unique ability to manufacture mesenchymal stem cells (MSCs) at scale, from one donor, one time, to create therapeutic grade stem cell treatments.
“We have a very comprehensive patent portfolio to protect our unique and proprietary IP and will continue to strengthen it with further applications,” said Dr Ross Macdonald, Cynata’s Chief Executive Officer. “The ability of the platform to enable manufacture of consistent, high-quality mesenchymal stem cell therapeutic products at scale is key to the ongoing development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide. Our phase I clinical trial in patients with steroid resistant graft-versus-host-disease (GvHD) is well underway and with further preclinical studies in progress there is significant opportunity to expand our IP.”
The inventors named on the patent are Dr Maxim Vodyanyk and Professor Igor Slukvin, founders, advisors and shareholders of Cynata.
Cynata anticipates that the patent will be granted by 14 September 2018, with an expiration date of 16 March 2031.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.